Britain and America have concluded a major commercial pact that will keep zero duties on British medicine exports going into the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to increase expenditure on medicines through the NHS. This pledge ensures that duties on these vital products will be held at zero for a timeframe of three years.
This agreement follows previous threats to hike import taxes on patented drug products, with increases discussed reaching 100%.
"This agreement between the United Kingdom reinforces the worldwide climate for innovative medicines and establishes much-needed fairness to transatlantic drug exports," a statement noted.
Economic Importance
Medicines constitute one of the the United Kingdom's most significant exports to the US, which is by far the largest buyer for major UK drugmakers.
Trade data indicate that in the one-year period to the end of September, the UK sold pharmaceutical products totaling billions to the US. This figure accounted for a significant portion of total UK exports in that span.
"This deal protects work, increases funding and paves the way for the UK to become a worldwide center for medical research," the Business and Trade Secretary remarked.
Detailed UK Commitments
The pact includes several specific changes from the UK:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it deems new therapies to be unaffordable by 25%.
- Boosted Medicine Funding: There is a target to double total health service expenditure on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Rebate Cap: The sum manufacturers must refund to the NHS to control costs will be restricted at 15%. Previously, repayments exceeded 20%.
Broader Context
The pact comes amid a long-running dispute between the sector and the UK government over medicine costs and regulatory access.
The disagreement were intensified by arguments that US consumers were paying several times more for the identical medicines than patients in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been paused or cancelled, while major funding commitments have been announced toward projects in the United States.
The Science Minister stated that the NHS must increase expenditure on treatments, noting that its budget allocation on drugs had declined as a proportion of its resources over the past decade.
